Literature DB >> 23205310

Inpatient burden of gastrointestinal stromal tumors in the United States.

Manasi Datar1, Rahul Khanna.   

Abstract

The purpose of this study was to determine the inpatient burden among patients with gastrointestinal stromal tumors (GISTs). The study assessed hospitalization rates of GISTs and compared hospital characteristics among patients with and without GISTs. Further, predictors of total charges and mortality among patients with GISTs were identified.The 2009 Healthcare Utilization Project Nationwide Inpatient Sample (HCUP-NIS) database was analyzed for this study. Inpatient burden among patients with GISTs (cases) was compared to that among patients without GISTs or any diagnosis of cancer (controls). Linear regression was used to determine the factors predicting total charges, and logistic regression was used to determine predictors of mortality. Analyses were performed using SAS version 9.2.In 2009, there were 14,562 hospitalizations among patients with GISTs at a rate of 44/100,000 admissions. Hospitalization rates among patients with GISTs varied by patient-, hospital-, and discharge-level characteristics. Patients with GISTs had longer length of stay (LOS), total charges, and mortality rate as compared to the control group. Total charges for hospitalizations among patients with GISTs varied by household income, hospital location and region, LOS, and number of diagnoses on record, respectively. When examining the predictors of mortality, household income, hospital region, and number of diagnoses on record emerged significant.By examining the inpatient burden among patients with GISTs, this study fills a critical gap in this area of research. Future studies could merge medical services claims data with cancer registry data to study in-depth the humanistic and economic burden associated with GISTs.

Entities:  

Keywords:  Gastrointestinal stromal tumors; charges; inpatient; mortality

Year:  2012        PMID: 23205310      PMCID: PMC3492477          DOI: 10.3978/j.issn.2078-6891.2012.037

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  16 in total

1.  Inequalities in access to medical care by income in developed countries.

Authors:  Eddy van Doorslaer; Cristina Masseria; Xander Koolman
Journal:  CMAJ       Date:  2006-01-17       Impact factor: 8.262

2.  Inpatient costs, length of stay, and mortality for cerebrovascular events in community hospitals.

Authors:  S D Reed; D K Blough; K Meyer; J G Jarvik
Journal:  Neurology       Date:  2001-07-24       Impact factor: 9.910

Review 3.  Cancer in rural versus urban populations: a review.

Authors:  A C Monroe; T C Ricketts; L A Savitz
Journal:  J Rural Health       Date:  1992       Impact factor: 4.333

Review 4.  Gastrointestinal stromal tumors.

Authors:  L Strickland; G D Letson; C A Muro-Cacho
Journal:  Cancer Control       Date:  2001 May-Jun       Impact factor: 3.302

5.  Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study.

Authors:  Geir Tryggvason; Hjörtur G Gíslason; Magnús K Magnússon; Jón G Jónasson
Journal:  Int J Cancer       Date:  2005-11-01       Impact factor: 7.396

6.  Use of health care services by lower-income and higher-income uninsured adults.

Authors:  Joseph S Ross; Elizabeth H Bradley; Susan H Busch
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

7.  Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden.

Authors:  Bengt Nilsson; Per Bümming; Jeanne M Meis-Kindblom; Anders Odén; Aydin Dortok; Bengt Gustavsson; Katarzyna Sablinska; Lars-Gunnar Kindblom
Journal:  Cancer       Date:  2005-02-15       Impact factor: 6.860

Review 8.  Gastrointestinal stromal tumor.

Authors:  Puneet Gupta; Mallika Tewari; Hari S Shukla
Journal:  Surg Oncol       Date:  2008-01-30       Impact factor: 3.279

9.  Cancers of affluence: positive social class gradient and rising incidence trend in some cancer forms.

Authors:  A H Rimpelä; E I Pukkala
Journal:  Soc Sci Med       Date:  1987       Impact factor: 4.634

10.  Disappearance of racial disparities in gastrointestinal stromal tumor outcomes.

Authors:  Michael C Cheung; Ying Zhuge; Relin Yang; Leonidas G Koniaris
Journal:  J Am Coll Surg       Date:  2009-05-28       Impact factor: 6.113

View more
  5 in total

1.  MicroRNA-218 inhibits gastrointestinal stromal tumor cell and invasion by targeting KIT.

Authors:  Rong Fan; Jie Zhong; Sichang Zheng; Zhengting Wang; Ying Xu; Shuyi Li; Jie Zhou; Fei Yuan
Journal:  Tumour Biol       Date:  2013-12-29

2.  MiR-137 regulates epithelial-mesenchymal transition in gastrointestinal stromal tumor.

Authors:  Sheng Liu; Juan Cui; Guoqing Liao; Yi Zhang; Ke Ye; Tailiang Lu; Jing Qi; Guohui Wan
Journal:  Tumour Biol       Date:  2014-06-12

3.  Assessment of the Accuracy of Disease Coding Among Patients Diagnosed With Sarcoma.

Authors:  Heather G Lyu; Leah A Stein; Lily V Saadat; Sheila N Phicil; Adil Haider; Chandrajit P Raut
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

Review 4.  The opportunities and shortcomings of using big data and national databases for sarcoma research.

Authors:  Heather G Lyu; Adil H Haider; Adam B Landman; Chandrajit P Raut
Journal:  Cancer       Date:  2019-05-15       Impact factor: 6.860

5.  microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway.

Authors:  Rong Fan; Jie Zhong; Sichang Zheng; Zhengting Wang; Ying Xu; Shuyi Li; Jie Zhou; Fei Yuan
Journal:  Clin Exp Med       Date:  2014-04-05       Impact factor: 3.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.